These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

107 related items for PubMed ID: 3092836

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Effects of CS-514, a new inhibitor of HMG CoA reductase, on plasma lipids, lipoproteins and apoproteins in patients with primary hypercholesterolemia.
    Kazumi T, Yoshino G, Kasama T, Iwatani I, Iwai M, Morita S, Baba S.
    Horm Metab Res; 1986 Sep; 18(9):654-5. PubMed ID: 3096862
    [No Abstract] [Full Text] [Related]

  • 3. Therapeutic efficacy of the HMG-CoA-reductase inhibitor pravastatin in hyperlipoproteinaemia type II.
    Saxenhofer H, Weidmann P, Riesen WF, Beretta-Piccoli C, Fragiacomo C, Wunderlin R, Noseda G.
    Eur J Clin Pharmacol; 1990 Sep; 39(2):101-5. PubMed ID: 2123791
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Efficacy and safety of pravastatin in patients with primary hypercholesterolemia. I. A dose-response study.
    Hunninghake DB, Knopp RH, Schonfeld G, Goldberg AC, Brown WV, Schaefer EJ, Margolis S, Dobs AS, Mellies MJ, Insull W.
    Atherosclerosis; 1990 Nov; 85(1):81-9. PubMed ID: 2126437
    [Abstract] [Full Text] [Related]

  • 8. The effect of HMG-CoA reductase inhibitor (CS-514) on the synthesis and secretion of apolipoproteins B and A-1 in the human hepatoblastoma Hep G2.
    Sato R, Imanaka T, Takano T.
    Biochim Biophys Acta; 1990 Jan 16; 1042(1):36-41. PubMed ID: 2153411
    [Abstract] [Full Text] [Related]

  • 9. Activity of low-density lipoprotein receptors as estimated from concentrations of apolipoprotein B and C-II in serum.
    Ito H, Naito C, Hayashi H, Kawamura M.
    Clin Chem; 1988 Nov 16; 34(11):2224-7. PubMed ID: 3141083
    [Abstract] [Full Text] [Related]

  • 10. Effect of pravastatin on serum lipids, apolipoproteins and lipoprotein (a) in patients with non-insulin dependent diabetes mellitus.
    Umeda F, Watanabe J, Inoue K, Hisatomi A, Mimura K, Yamauchi T, Sako Y, Kunisaki M, Tajiri Y, Nawata H.
    Endocrinol Jpn; 1992 Feb 16; 39(1):45-50. PubMed ID: 1535040
    [Abstract] [Full Text] [Related]

  • 11. The relationship between apolipoprotein B-100 and low-density lipoprotein cholesterol after treatment with an HMG CoA reductase inhibitor.
    Levinson SS, Blevins RD, Smith MP, Rubinfire M, Maciejko JJ.
    Am J Clin Pathol; 1989 Oct 16; 92(4):479-83. PubMed ID: 2508466
    [Abstract] [Full Text] [Related]

  • 12. Efficacy and safety of pravastatin in patients with primary hypercholesterolemia. II. Once-daily versus twice-daily dosing.
    Hunninghake DB, Mellies MJ, Goldberg AC, Kuo PT, Kostis JB, Schrott HG, Insull W, Pan HY.
    Atherosclerosis; 1990 Dec 16; 85(2-3):219-27. PubMed ID: 2129319
    [Abstract] [Full Text] [Related]

  • 13. Effect of pravastatin sodium, a new inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A reductase, on very-low-density lipoprotein composition and kinetics in hyperlipidemia associated with experimental nephrosis.
    Hirano T, Komuro F, Furukawa S, Nagano S, Takahashi T.
    Metabolism; 1990 Jun 16; 39(6):605-9. PubMed ID: 2112675
    [Abstract] [Full Text] [Related]

  • 14. Once-daily pravastatin in patients with primary hypercholesterolemia: a dose-response study.
    Jones PH, Farmer JA, Cressman MD, McKenney JM, Wright JT, Proctor JD, Berkson DM, Farnham DJ, Wolfson PM, Colfer HT.
    Clin Cardiol; 1991 Feb 16; 14(2):146-51. PubMed ID: 1904333
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Effects of CS-514 (eptastatin), an inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase, on serum lipid and apolipoprotein levels in heterozygous familial hypercholesterolemic patients treated by low density lipoprotein (LDL)-apheresis.
    Mabuchi H, Fujita H, Michishita I, Takeda M, Kajinami K, Koizumi J, Takeda R, Takegoshi T, Wakasugi T, Ueda K.
    Atherosclerosis; 1988 Aug 16; 72(2-3):183-8. PubMed ID: 3145745
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Plasma lipoprotein changes after treatment with pravastatin and gemfibrozil in patients with familial hypercholesterolemia.
    Franceschini G, Sirtori M, Vaccarino V, Gianfranceschi G, Chiesa G, Sirtori CR.
    J Lab Clin Med; 1989 Sep 16; 114(3):250-9. PubMed ID: 2504855
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Effect of fluvastatin on intermediate density lipoprotein (remnants) and other lipoprotein levels in hypercholesterolemia.
    Broyles FE, Walden CE, Hunninghake DB, Hill-Williams D, Knopp RH.
    Am J Cardiol; 1995 Jul 13; 76(2):129A-135A. PubMed ID: 7604788
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.